natgillin/translations-raw huggingface dataset:
Safety of ReFacto AF was evaluated in previously treated children and adolescents (n=18, age 12-16 years in a study and n=49, age 7-16 years in a supporting study).
Sigurnost lijeka ReFacto AF bila je procijenjena u prethodno liječene djece i adolescenata (n=18, u dobi od 12 do 16 godina u jednom ispitivanju i n=49, u dobi od 7 do 16 godina u potpornom ispitivanju).
Safety pharmacology studies showed no effect of agomelatine on hERG (human Ether à-go-go Related Gene) current or on dog Purkinje cells action potential.
Sigurnosne farmakološke studije pokazale su da agomelatin nema utjecaja na hERG (humani Ether à- go-go Related Gene) potencijal ili na akcijski potencijal Purkinjeovih stanica u pasa.
Safety population, on treatment
Populacija u ispitivanju sigurnosti, na liječenju
Safety population, on treatment
Sigurnosna populacija, na liječenju
Safety results are expressed as the number of patients with an adverse reaction per 100 patient- years of exposure (except for injection site reactions).
Sigurnosni rezultati su izraženi kao broj bolesnika koji su imali neku nuspojavu na 100 bolesnik-godina izloženosti (osim za reakcije na mjestu injiciranja).
Safety tips
Savjeti za sigurnu primjenu
Safety Tips
Upute za sigurnu primjenu
Safety updates to coincide with PSUR timetable.
Nadopune sigurnosnih informacija moraju se podudarati s rokovima podnošenja PSUR-a.
Safety was assessed in a controlled clinical study enrolling renal transplant patients below 18 years of age considered of high immunologic risk, defined as a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy (see section 5.1).
Sigurnost primjene ispitana je u kontroliranom kliničkom ispitivanju koje je uključivalo bolesnike s presađenim bubregom u dobi ispod 18 godina s povišenim imunološkim rizikom, što je definirano jednom ili više epizoda akutnog odbacivanja alopresatka i/ili prisutnost kronične nefropatije alopresatka potvrđene biopsijom u anamnezi (vidjeti dio 5.1).
Safety was assessed in a controlled clinical study enrolling renal transplant patients below 18 years of age considered of high immunologic risk, defined as a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy (see section 5.1).
Sigurnost primjene ispitana je u kontroliranom kliničkom ispitivanju koje je uključivalo bolesnike s presađenim bubregom u dobi ispod 18 godina s povišenim imunološkim rizikom, što je definirano jednom ili više epizoda akutnog odbacivanja alopresatka i/ili prisutnošću kronične nefropatije alopresatka potvrđene biopsijom u anamnezi (vidjeti dio 5.1).
Safety was considered acceptable, provided agreed measures were followed.
Zaključeno je da je razina sigurne primjene prihvatljiva, ukoliko se korisnici pridržavaju dogovorenih mjera.
Safety was demonstrated in breeding, pregnant and lactating animals treated at 28-day intervals with multiple consecutive doses up to 3 times the maximum recommended dose.
Neškodljivost je dokazana kod rasplodnih i gravidnih životinja te onih koje doje, tretiranih u razmacima od 28 dana s višestrukim, uzastopnim dozama, do 3 maksimalno preporučene doze.
Safety was demonstrated in kitten aged 11-13 weeks and weighing 1.2-1.5 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals).
Neškodljivost je dokazana kod mačića starosti 11 - 13 tjedana i težine 1,2 - 1,5 kg tretiranih trokratno s 5 x većim dozama od maksimalno preporučene doze i u kraćim intervalima od preporučenih (8- tjedni intervali).
Safety was demonstrated in puppies aged 8–9 weeks and weighing 2.0–3.6 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals).
Neškodljivost je dokazana u štenadi stare 8 do 9 tjedana i težine 2,0-3,6 kg tretiranih trokratno s 5 x većim dozama od maksimalno preporučene doze i u kraćim intervalima od preporučenih (8-tjedni intervali).
Safety was demonstrated in puppies aged 8–9 weeks and weighing 2.0–3.7 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals).
Neškodljivost je dokazana u štenadi stare 8 do 9 tjedana i težine 2,0 - 3,7 kg tretiranih trokratno s 5 x većim dozama od maksimalno preporučene doze i u kraćim intervalima od preporučenih (8-tjedni intervali).
Safety was evaluated in an observational study that included 69,237 children vaccinated with ProQuad 12 months to 12 years old and 69,237 matched children in a historical comparison group who were vaccinated concomitantly with the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc., and the Varicella Vaccine live (Oka/Merck).
Sigurnost se procijenila u opažajnom ispitivanju koje je uključilo 69 237 djece cijepljene cjepivom ProQuad u dobi od 12 mjeseci do 12 godina i 69 237 djece odgovarajuće dobi i spola u povijesnoj usporednoj skupini koji su bili istodobno cijepljeni cjepivom protiv morbila, parotitisa i rubele proizvođača Merck & Co., Inc. i živim cjepivom protiv varičele (Oka/Merck).
Safety, efficacy and pharmacokinetic profiles of the two dose regimens were assessed after 3 weeks of therapy in each patient.
U svakog su bolesnika nakon 3 tjedna liječenja procijenjeni sigurnost, djelotvornost i farmakokinetički profil sheme od dvije doze.
Safety, efficacy and pharmacokinetics of follitropin alfa in patients with renal or hepatic impairment have not been established.
Sigurnost, djelotvornost i farmakokinetika folitropina alfa nije utvrđena u pacijenata s bolesti jetre ili bubrega.
Safety, efficacy and pharmacokinetics of follitropin alfa in patients with renal or hepatic impairment have not been established.
Sigurnost, djelotvornost i farmakokinetika folitropina alfa u pacijenata s oštećeneom funkcijom bubrega ili jetre nisu ustanovljene.
Safety, efficacy and pharmacokinetics of GONAL-f in patients with renal or hepatic impairment have not been established.
Sigurnost, djelotvornost i farmakokinetika lijeka GONAL-f nije utvrđena u pacijenata s bolesti jetre ili bubrega.
Safety, efficacy and pharmacokinetics of Ovitrelle in patients with renal or hepatic impairment have not been established.
Sigurnost, djelotvornost i farmakokinetika lijeka Ovitrelle u pacijenata s oštećenjem bubrega ili jetre nije utvrđena.
Safety, efficacy, and pharmacokinetics of Pergoveris in patients with renal or hepatic impairment have not been established.
Sigurnost, djelotvornost i farmakokinetika lijeka Pergoveris nije utvrđena u pacijenata s oštećenjem bubrega ili jetre.
Safin- amide
safinami d
Safinamide
afinamid
Safinamide absorption is rapid after single and multiple oral dosing, reaching Tmax in the time range 1.8-2.8 h after dosing under fasting conditions.
Apsorpcija safinamida je brza nakon jednog i više peroralnih doziranja, dostižući Tmax u rasponu vremena od 1,8 - 2,8 h nakon doziranja na tašte.
Safinamide did not present genotoxic potential in in vivo and in several in vitro systems using bacteria or mammalian cells.
Safinamid nije predstavljao genotoksični potencijal ni u in vivo ni u nekoliko in vitro sustava koji koriste bakterije ili stanice sisavaca.
Safinamide exposure in patients with mild hepatic disease increased marginally (30% in AUC), while in patients with moderate hepatic impairment exposure increased by approximately 80% (see section 4.2).
Izloženost safinamidu u bolesnika s blagim bolestima jetre neznatno se povećala (30% u AUC-u), dok je u bolesnika s umjerenim oštećenjem jetre izloženost povećana za oko 80% (vidjeti dio 4.2).
Safinamide is associated with state-dependent inhibition of voltage-gated sodium (Na+) channels, and modulation of stimulated release of glutamate.
Safinamid je povezan s inhibicijom ovisnom o stanju natrijskih (Na+) kanala reguliranih naponom i modulaciji stimuliranog oslobađanja glutamata.
Safinamide is expected to be excreted in milk as adverse reactions have been observed in rat pups exposed via milk (see section 5.3).
Očekuje se da se safinamid izlučuje u mlijeko, jer su nuspojave uočene u mladunaca štakora izloženim preko mlijeka (vidjeti dio 5.3).
Safinamide may transiently inhibit BCRP in vitro.
Safinamid može prolazno inhibirati BCRP in vitro.
Safinamide transiently inhibits BCRP in the small intestine (see section 4.5). .
Safinamid prolazno inhibira BCRP u tankom crijevu (vidjeti dio 4.5).
Safinamide used as an adjunct to levodopa may potentiate the side effects of levodopa, and pre- existing dyskinesia may be exacerbated, requiring a decrease of levodopa.
Safinamid primijenjen kao dodatni lijek uz levodopu može pojačati nuspojave levodope, a već postojeća diskinezija može se pogoršati, zahtijevajući smanjenje levodope.
Safinamide’s metabolism is not dependent on Cytochrome P450 (CYP) based enzymes.
Metabolizam safinamida ne ovisi o enzimima citokroma P450 (CYP).
Sage house, 319 Pinner road, Harrow, HA1 4HF United Kingdom
Sage house, 319 Pinner road, Harrow, HA1 4HF Velika Britanija
Sage House, 319 Pinner Road, North Harrow, HA1 4 HF, Middlesex United Kingdom
Sage House, 319 Pinner Road, North Harrow, HA1 4 HF, Middlesex Ujedinjeno Kraljevstvo
Sage House, 319 Pinner Road, North Harrow, Middlesex, HA1 4HF United Kingdom
Sage House, 319 Pinner Road, North Harrow, Middlesex, HA1 4HF Velika Britanija
Salicylates (e.g. aspirin)
alicilate (primjerice aspirin)
Salicylates (e.g. aspirin).
alicilate (primjerice aspirin)
Salicylates (e.g. aspirin).
Salicilate (npr. aspirin).
Salicylates (used to relieve pain and lower fever)
alicilate (koriste se za ublažavanje boli i snižavanje povišene tjelesne temperature)
Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites.
Salicilatna kiselina se primarno konjugira u jetri u saliciluričnu kiselinu, fenolni glukuronid, acil glukuronid i niz drugih manje zastupljenih metabolita.
Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites.
Salicilatna kiselina se u jetri primarno konjugira u saliciluričnu kiselinu, fenolni glukuronid, acil glukuronid i niz drugih manje zastupljenih matabolita.
Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites.
Salicilatna kiselina se u jetri primarno konjugira u saliciluričnu kiselinu, fenolni glukuronid, acil glukuronid i niz drugih manje zastupljenih metabolita.
Saline buffer
Puferska sol
Saline buffer
Puferska sol.
Saline n = 13
fiziološka otopina n = 13
Salivary hypersecretion
Prekomjerno lučenje sline
Salivary hypersecretion,, Abdominal pain, Constipation, Dry mouth
pojačana sekrecija sline, bolovi u abdomenu, konstipacija, suha usta
Salivation may occasionally occur if the animal licks the application site immediately after treatment.
Ako životinja liže mjesto aplikacije neposredno nakon tretiranja može se javiti slinjenje.
Salivation, vomiting and neurological signs (tremor) were observed occasionally when the product was administered at up to 10 times the recommended dose in adult cats and up to 5 times the recommended dose in kittens.
Slinjenje, povraćanje i drhtanje uočeni su povremeno kada je proizvod primijenjen u dozi do 10 puta većoj od preporučene kod odraslih mačaka i pet puta veće doze od preporučene kod mačića.
Salivation, vomiting and neurological signs (tremor) were observed occasionally when the product was administered at up to 10 times the recommended dose in adult cats and up to 5 times the recommended dose in kittens.
Slinjenje, povraćanje i neurološki simptomi (tremor) uočeni su kod mačaka kojima je proizvod apliciran u 10 x većoj dozi od preporučene, kod odrasle mačke i 5 x većoj dozi od preporučene, kod mačića.
Salmeterol
delamanid).
Salmeterol
Kortikosteroidi
Salmeterol
Mehanizam nepoznat
Salmeterol
Takrolimus
Salmeterol (medicine to treat asthma)
almeterol (lijek za liječenje astme)
Salmeterol and FP significantly reduced exacerbation rates compared with placebo by 15% (95% CI: 7% to 22%; p<0.001) and 18% (95% CI: 11% to 24%; p<0.001) respectively.
Salmeterol i FP značajno su smanjili stope egzacerbacija u usporedbi s placebom za 15% (95% CI: 7% do 22%; p<0,001) odnosno 18% (95% CI: 11% do 24%; p<0,001).
Salmeterol is a long-acting bronchodilator.
Salmeterol je dugodjelujući bronhodilatator.
Salmeterol Ritonavir inhibits CYP3A4 and as a result a pronounced increase in the plasma concentrations of salmeterol is expected.
Salmeterol Ritonavir inhibira CYP3A4 te se stoga očekuje znatan porast koncentracija salmeterola u plazmi.
Salmeterol/fluticasone 2 x 25/125 µg bd + terbutaline
Salmeterol/flutikazon 2 x 25/125 µg dvaput dnevno
Salmeterol/Fluticasone propionate - Asthma clinical trials
Salmeterol/Flutikazonpropionat – klinička ispitivanja astme
Salmeterol/fluticasone propionate COPD - clinical trials
Klinička ispitivanja salmeterola/flutikazonpropionata u KOPB-u
salmeterol/fluticasone propionate Inhalation use
salmeterol/flutikazonpropionat U dišne putove
Salmeterol:
Deksametazon
Salmeterol:
lopinavirom/ritonavirom.
Salmon, oval film-coated tablets debossed with ‘SP’ on one side and ‘150’ on the other side.
Boje lososa, ovalne filmom obložene tablete s utisnutim 'SP' na jednoj strani i '150' na drugoj strani.
Salmon-coloured, triangular, film-coated tablet engraved with “7.5” on one face and  on the other face.
Trokutasta filmom obložena tableta boje lososa s utisnutom oznakom “7,5” na jednoj strani, a  na drugoj.
Salmon-coloured, triangular, film-coated tablet engraved with “7.5” on one face and  on the other face.
Trokutasta filmom obložena tableta boje lososa s utisnutom oznakom “7.5” na jednoj strani, a  na drugoj.
Salo
Salo,
Salt and water retention causing swelling and raised blood pressure (shown on medical examination) and low potassium level in the blood
zadržavanje soli i vode što uzrokuje oticanje i povišeni krvni tlak (vidljivo u nalazima pretraga) i niska razina kalija u krvi
Salutas Pharma GmbH Otto-von-Guericke-Allee 1 D-39179 Barleben Germany
Salutas Pharma GmbH Otto-von-Guericke-Allee 1 D-39179 Barleben Njemačka
Samarium (153Sm) lexidronam pentasodium : 1.3 GBq/ml at reference date. (Corresponding to 20 to 80 µg/ml of samarium)
samarijev (153Sm) leksidronam, pentanatrijeva sol : 1,3 GBq/ml na referentni datum. (što odgovara 20 do 80 µg/ml samarija)
Samarium specific activity is approximately 16 – 65 MBq/µg of samarium.
Specifična aktivnost samarija iznosi približno 16 – 65 MBq/µg samarija.
Same number of 1 mL solvent syringes and sterile vial adapters
Isti broj napunjenih štrcaljki od 1 ml s otapalom i sterilnim adapterima za bočice
Same number of 1 mL solvent syringes and sterile vial adapters
Isti broj štrcaljki s otapalom od 1 ml i sterilnim adapterima za bočice
Sample Inlet
Unos uzoraka
Sample preparation for (IRMS)
Priprema uzoraka za (IRMS)
Sample preparation for Infrared Spectroscopy (NDIR)
Priprema uzoraka za infracrvenu spektroskopiju (NDIR)
Samples for total antibody will be collected at specific intervals.
Uzorci za određivanje ukupnih antitijela prikupljat će se u određenim
Samples from those subjects who have a consistent increase in urinary GAG values together with high antibody levels will have their antibody samples assessed for evidence of neutralizing
Uzorci prikupljeni od ispitanika kod kojih je konzistentni porast vrijednosti urinarnog GAG-a zajedno s visokim razinama antitijela će se procijeniti i uzorci antitijela će se pregledati da se vidi imali li dokaza za postojanje neutralizirajućih aktivnosti.
Sampling time: 00-minute-value Sampling time: 30-minute-value
prijenos uzoraka izdahnutog zraka za analizu: Vrijeme uzorkovanja: 00-minutna vrijednost Vrijeme uzorkovanja: 30-minutna vrijednost
Sampling time: 00-minute-value Sampling time: 30-minute-value
Vrijeme uzorkovanja: 00-minutna vrijednost Vrijeme uzorkovanja: 30-minutna vrijednost
Samsca 15 mg is a blue, triangular, convex tablet, with “OTSUKA” and “15” on one side.
Samsca 15 mg je plava, trokutasta, konveksna tableta s utisnutim "OTSUKA" i "15" s jedne strane.
Samsca 15 mg tablets Samsca 30 mg tablets tolvaptan
Samsca 15 mg tablete Samsca 30 mg tablete tolvaptan
Samsca 30 mg is a blue, round, convex tablet, with “OTSUKA” and “30” on one side.
Samsca 30 mg je plava, okrugla, konveksna tableta s utisnutim "OTSUKA" i "30" s jedne strane.
Samsca causes water loss because it increases your urine production.
Samsca uzrokuje gubitak vode jer povećava stvaranje urina.
Samsca contains lactose.
Samsca sadrži laktozu.
Samsca is unlikely to adversely affect your ability to drive a car or to operate machinery.
Samsca najvjerojatnije neće negativno utjecati na vašu sposobnost da vozite automobil ili rukujete strojevima.
Samsca may increase the effect of digoxin (used for treatment of irregularities of heart beat and heart failure).
Samsca može pojačati učinak digoksina (koji se koristi za liječenje nepravilnosti otkucaja srca i zatajenja srca).
Samsca may reduce the effect of desmopressin (used to increase blood clotting factors).
Samsca može smanjiti djelovanje dezmopresina (koristi se za povećanje faktora zgrušavanja krvi).
Samsca must not be used during pregnancy (see section 4.3).
Samsca se ne smije koristiti za vrijeme trudnoće (vidjeti dio 4.3).
Samsca should not be taken with grapefruit juice (see section 4.5).
Samsca se ne smije uzimati sa sokom od grejpfruta (vidjeti dio 4.5).
SANCUSO 3.1 mg/24 hours transdermal patch Granisetron
SANCUSO 3,1 mg/24 sata transdermalni flaster granisetron
SANCUSO belongs to a group of medicines called antiemetics and antinauseants.
SANCUSO pripada skupini lijekova koji se nazivaju antiemetici i sredstva protiv mučnine.
SANCUSO has no or negligible affect on your ability to drive or use any machines.
SANCUSO ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada na strojevima.
SANCUSO has no or negligible influence on the ability to drive and use machines.
SANCUSO ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
SANCUSO is a transdermal (skin) patch used to prevent nausea (feeling sick) and vomiting (being sick) in adults receiving chemotherapy treatments (medicines to treat cancer) lasting 3 to 5 days and who have difficulty swallowing tablets (for example due to soreness, dryness or inflammation of the mouth or throat).
SANCUSO je transdermalni (za primjenu kroz kožu) flaster koji se koristi za sprječavanje mučnine i povraćanja u odraslih osoba koje primaju kemoterapiju (lijekove za liječenje raka) koja traje 3 do 5 dana i koji imaju poteškoća u gutanju tableta (zbog, na primjer, osjetljivosti, suhoće ili upale usne šupljine ili grla.
SANCUSO is for transdermal use.
Lijek SANCUSO namijenjen je za primjenu kroz kožu.
Sand flies, mosquitoes and stable flies:
Papatači, komarci i stajske muhe
Sand flies, mosquitoes and stable flies:
Papatači, komarci i stajske muhe:
Sanderson Road Uxbridge UB8 1DH United Kingdom
Sanderson Road Uxbridge UB8 1DH Ujedinjeno Kraljevstvo
Sanderson Road Uxbridge UB8 1DH United Kingdom
Sanderson Road Uxbridge UB8 1DH Velika Britanija
Sandoz GmbH Biochemiestrasse 10 A-6250 Kundl Austria
Sandoz GmbH Biochemiestraße 10 A-6250 Kundl Austrija
Sandoz GmbH Biochemiestraße 10 A-6250 Kundl Austria
Sandoz GmbH Biochemiestraße 10 A-6250 Kundl
Sandoz GmbH, Biochemiestrasse 10, A-6250 Kundl, Austria
Sandoz GmbH, Biochemiestrasse 10, A-6250 Kundl, Austrija
Sandoz N.V. Telecom Gardens Medialaan 40
Telecom Gardens Medialaan 40
Sandoz nv/sa Medialaan 40
Medialaan 40
Sandoz Pharmaceuticals d.d. filialas Šeimyniškių 3A,
Sandoz Pharmaceuticals d.d. filialas Šeimyniškių 3 A,
Sandwich, Kent CT13 9NJ United Kingdom
Sandwich, Kent CT13 9NJ Ujedinjeno Kraljevstvo
Sandwich, Kent, CT13 9NJ United Kingdom
Sandwich, Kent CT13 9NJ Ujedinjeno Kraljevstvo
Sandwich, Kent, CT13 9NJ United Kingdom
Sandwich, Kent, CT13 9NJ Ujedinjeno Kraljevstvo
Sanford, NC 27330 USA
Sanford, NC 27330 SAD
Sanofi - Produtos Farmacêuticos, Lda.
Sanofi - Produtos Farmacêuticos, Lda..
Sanofi Chimie Route d’Avignon 30390 Aramon France
Sanofi Chimie Route d’Avignon 30390 Aramon Francuska
Sanofi Clir SNC 54, rue La Boétie F-75008 Paris France
Sanofi Clir SNC 54, rue La Boétie F-75008 Paris Francuska
Sanofi Pasteur
Sanofi Pasteur‌
Sanofi Pasteur - Parc Industriel d’Incarville - 27100 Val-de-Reuil - France
Sanofi Pasteur, Parc Industriel d'Incarville, 27 100 Val-de-Reuil, Francuska
Sanofi Pasteur Europe, 2 Avenue Pont Pasteur, 69007 Lyon, France
Sanofi Pasteur Europe, 2 Avenue Pont Pasteur, 69007 Lyon, Francuska
Sanofi Pasteur Europe, 2 Avenue Pont Pasteur, 69007 Lyon, France.
Sanofi Pasteur Europe, 2 Avenue Pont Pasteur, 69007 Lyon, Francuska.
Sanofi Pasteur MSD GmbH, Tel:
Sanofi Pasteur MSD S.A., Tel: +34.91.371.78.00
Sanofi Pasteur MSD GmbH, Tel: +43 1 890 34
Sanofi Pasteur MSD, Tel: +31.23.567.96.00
Sanofi Pasteur MSD GmbH, Tel: +43 1 890 34 91
Sanofi Pasteur MSD, Tel: +31.23.567.96.00
Sanofi Pasteur MSD GmbH, Tel: +49 30 499198-
Sanofi Pasteur MSD S.A., Tel: +34.91.371.78.00
Sanofi Pasteur MSD GmbH, Tel: +49 30 499198-0
Sanofi Pasteur MSD S.A., Tel: +34.91.371.78.00
Sanofi Pasteur MSD GmbH, Tel: +49 30 499198-0
Sanofi Pasteur MSD, Tel: +31.23.567.96.00
Sanofi Pasteur MSD Ltd, Tel:
Sanofi Pasteur MSD Ltd, Tel: +44.1.628.785.291
Sanofi Pasteur MSD Ltd, Tel: +3531.468.5600
Sanofi Pasteur MSD, SA, Tel: +351.21.470.45.50
Sanofi Pasteur MSD SNC, 162 avenue Jean Jaurès, 69007 Lyon, France
Sanofi Pasteur MSD SNC, 162 avenue Jean Jaurès, 69007 Lyon, Francuska
Sanofi Pasteur MSD SNC, 162 avenue Jean Jaurès, 69007 LYON, France.
Sanofi Pasteur MSD SNC, 162 avenue Jean Jaurès, 69007 Lyon, Francuska
Sanofi Pasteur MSD SNC, 162 avenue Jean Jaurès, 69007 LYON, France.
Sanofi Pasteur MSD SNC, 162 avenue Jean Jaurès, 69007 LYON, Francuska.
Sanofi Pasteur MSD SNC, Tél: +33.4.37.28.40.00
Sanofi Pasteur MSD, SA, Tel: +351.21.470.45.50
Sanofi Pasteur MSD Spa, Tel: +39.06.664.092.11
Tel: +421.2.58282010
Sanofi Pasteur MSD, SA, Tel: +351.21.470.45.50
Sanofi Pasteur MSD, Tlf: +47.67.50.50.20
Sanofi Pasteur MSD, Tel: +31.23.567.96.00
Sanofi Pasteur MSD SNC, Tél: +33.4.37.28.40.00
Sanofi Pasteur MSD, Tel: +46.8.564.888.60
Sanofi Pasteur MSD, Puh/Tel: +358.9.565.88.30
Sanofi Pasteur MSD, Tlf: +45 23 32 69 29 Merck Sharp & Dohme Cyprus Limited
Merck Sharp & Dohme OÜ Tel: +372.614.4200
Sanofi Pasteur MSD, Tlf: +47.67.50.50.20
Sanofi Pasteur MSD, Tél: +32.2.726.95.84
Sanofi Pasteur SA
Sanofi Pasteur
Sanofi Pasteur SA, 1541 avenue Marcel Mérieux, 69280 Marcy l'Etoile, France Sanofi Pasteur SA, Parc Industriel d'Incarville, 27100 Val de Reuil, France
Sanofi Pasteur SA, 1541 avenue Marcel Mérieux, 69280 Marcy l'Etoile, Francuska Sanofi Pasteur SA, Parc Industriel d'Incarville, 27100 Val de Reuil, Francuska
Sanofi Pasteur SA, 2 avenue Pont Pasteur, 69007 Lyon , France
Sanofi Pasteur SA, 2 avenue Pont Pasteur, 69007 Lyon, Francuska
Sanofi Pasteur SA, 2 avenue Pont Pasteur, 69007 Lyon, France
Sanofi Pasteur SA, 2 avenue Pont Pasteur, 69007 Lyon, Francuska
Sanofi Pasteur SA, 2 avenue Pont Pasteur, 69007 Lyon, France
Sanofi Pasteur SA, 2, avenue Pont Pasteur, F-69007 Lyon, Francuska
Sanofi Pasteur SA, 2, avenue Pont Pasteur, F-69007 Lyon, France.
Sanofi Pasteur SA, 2, avenue Pont Pasteur, F-69007 Lyon, Francuska.
Sanofi Pasteur, Campus Mérieux – 1541, avenue Marcel Mérieux – 69280 Marcy l’Etoile - France
Sanofi Pasteur, Campus Mérieux, 1541 avenue Marcel Mérieux, 69280 Marcy L`Etoile, Francuska
Sanofi Romania SRL Tel: +40 (0) 21 317 31 36
Sanofi Romania SRL Tel: +40 (0)21 317 31 36
Sanofi S.p.A. Località Valcanello 03012 Anagni (FR) Italy
Sanofi S.p.A. Località Valcanello 03012 Anagni (FR) Italija
Sanofi S.p.A. Località Valcanello 03012 Anagni (FR) Italy
Sanofi S.p.A. Località Valcanello 03012 Anagni (FR) Italija‌
Sanofi S.p.A., Località Valcanello, 03012 Anagni (FR), Italy.
Sanofi S.p.A., Località Valcanello, 03012 Anagni (FR), Italija
Sanofi Synthelabo Limited Edgefield Avenue
Sanofi Synthelabo Limited Edgefield Avenue‌‌
Sanofi Winthrop Industrie 1051 Boulevard Industriel
Za napunjene štrcaljke Sanofi Winthrop Industrie 1051 Boulevard Industriel